Thursday, June 26, 2014
Publication and contact
Head and neck cancer;
Retinoid X receptor (RXR);
acid receptor-g (RARG)
In vitro and mouse studies suggest combining RXR and RARG
agonists could help prevent oral and esophageal squamous cell carcinomas. In
a mouse model of oral carcinogenesis, an RARG agonist plus the RXR agonist Targretin
decreased the number of malignant lesions and their severity compared with
the RARG agonist alone or no treatment. The agonists also decreased markers
of cancer and oxidative stress compared with no treatment. Next steps could
include evaluating the combination strategy in additional cancer models.
Co. Ltd. markets Targretin to treat cutaneous T cell
Co. Ltd. has the oral RARG and RXR agonist peretinoin
in Phase III testing to treat liver cancer.
Therapeutics Inc. has the RXR agonist IRX4204
in Phase II or earlier testing to treat various cancers.
Pharmaceuticals Inc. have the RARG agonist palovarotene
in Phase II testing to treat musculoskeletal indications.
Published online June 26, 2014
Patent and licensing status
Tang, X.-H. et al. Proc.
Natl. Acad. Sci. USA; published online June 3, 2014;
Contact: Lorraine J. Gudas, Weill Cornell Medical College,
New York, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]